1. Home
  2. IVVD vs MRVI Comparison

IVVD vs MRVI Comparison

Compare IVVD & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • MRVI
  • Stock Information
  • Founded
  • IVVD 2020
  • MRVI 2014
  • Country
  • IVVD United States
  • MRVI United States
  • Employees
  • IVVD N/A
  • MRVI N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • MRVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • IVVD Health Care
  • MRVI Health Care
  • Exchange
  • IVVD Nasdaq
  • MRVI Nasdaq
  • Market Cap
  • IVVD 351.6M
  • MRVI 376.2M
  • IPO Year
  • IVVD 2021
  • MRVI 2020
  • Fundamental
  • Price
  • IVVD $1.75
  • MRVI $3.49
  • Analyst Decision
  • IVVD Strong Buy
  • MRVI Hold
  • Analyst Count
  • IVVD 5
  • MRVI 9
  • Target Price
  • IVVD $5.11
  • MRVI $4.54
  • AVG Volume (30 Days)
  • IVVD 5.6M
  • MRVI 1.7M
  • Earning Date
  • IVVD 11-13-2025
  • MRVI 11-06-2025
  • Dividend Yield
  • IVVD N/A
  • MRVI N/A
  • EPS Growth
  • IVVD N/A
  • MRVI N/A
  • EPS
  • IVVD N/A
  • MRVI N/A
  • Revenue
  • IVVD $46,210,000.00
  • MRVI $219,830,000.00
  • Revenue This Year
  • IVVD $112.35
  • MRVI N/A
  • Revenue Next Year
  • IVVD $272.14
  • MRVI $7.27
  • P/E Ratio
  • IVVD N/A
  • MRVI N/A
  • Revenue Growth
  • IVVD 1941.08
  • MRVI N/A
  • 52 Week Low
  • IVVD $0.35
  • MRVI $1.67
  • 52 Week High
  • IVVD $2.74
  • MRVI $8.54
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 64.77
  • MRVI 67.76
  • Support Level
  • IVVD $1.56
  • MRVI $3.21
  • Resistance Level
  • IVVD $2.01
  • MRVI $3.46
  • Average True Range (ATR)
  • IVVD 0.19
  • MRVI 0.21
  • MACD
  • IVVD 0.03
  • MRVI 0.02
  • Stochastic Oscillator
  • IVVD 72.92
  • MRVI 82.42

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Share on Social Networks: